41 Results for "

αvβ6

" in MedChemExpress (MCE) Product Catalog:
Products (41)

41 Results for "αvβ6" in MCE Product Catalog:

  • Isoforms Recommended:
75
75 Publications Verification
Cat. No.: HY-16141
CAS No.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
75
75 Publications Verification
Cat. No.: HY-16143
CAS No.: 199807-35-7
Synonyms: EMD 121974 TFA
Cilengitide TFA (EMD 121974 TFA) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide TFA inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide TFA inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide TFA can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-18644
CAS No.: 1564286-55-0
Target:  

Integrin

Research Areas:  

Cancer

CWHM-12 is a potent inhibitor of αV integrins with IC50s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15102
CAS No.: 227963-15-7
Purity:  99.50%
Synonyms: L-000845704
Target:  

Integrin

Research Areas:  

Inflammation/Immunology Cancer

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-137561
CAS No.: 2376257-44-0
Purity:  99.67%
Synonyms: PLN-74809
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19767
CAS No.: 1629249-33-7
GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19767A
CAS No.: 1629249-40-6
GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101473
CAS No.: 851333-14-7
Purity:  99.94%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700762
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ITGAV; Integrin, Alpha V (Vitronectin Receptor, Alpha Polypeptide, Antigen CD51); Prev. MSK8; Vitronectin Receptor; Prev. VNRA; Integrin AlphaVbeta3; Prev. VTNR; Integrin, Alpha V; Vitronectin Receptor Subunit Alpha; CD51 Antigen; Integrin Alpha-V; IDNDC
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-W087027
CAS No.: 1295584-83-6
Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [ 68Ga]Ac-CG6 formed by the conjugation of 68Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P990667
CAS No.: 1439902-67-6
Synonyms: BG00011

Target:  

Integrin TGF-beta/Smad

Research Areas:  

Inflammation/Immunology Cancer

STX-100 (BG00011) is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .
loading...
    loading...
Cat. No.: HY-130119
CAS No.: 2378617-67-3
Target:  

Integrin

Research Areas:  

Cancer

Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively .
loading...
    loading...
Cat. No.: HY-100133A
Purity:  96.18%
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .
loading...
    loading...
Cat. No.: HY-P1654
CAS No.: 932699-03-1
Target:  

Integrin

Research Areas:  

Cancer

A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-P6351
Target:  

Integrin

Research Areas:  

Cancer

c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic .
loading...
    loading...
Cat. No.: HY-W008201
CAS No.: 59379-02-1
tert-Butyl 3-formylpyrrolidine-1-carboxylate is a drug intermediate that can be used for the synthesis nonpeptidic αvβ6 Integrin inhibitors .
loading...
    loading...
Cat. No.: HY-117133
CAS No.: 1621332-91-9
Synonyms: SF0166
Target:  

Integrin

Research Areas:  

Metabolic Disease

Nesvategrast (SF0166) is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. Nesvategrast inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. Nesvategrast decreases neovascularization in the oxygen-induced retinopathy mouse model .
loading...
    loading...
Cat. No.: HY-D2062
CAS No.: 1448146-89-1
ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .
loading...
    loading...
Cat. No.: HY-153807
CAS No.: 313709-47-6
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC50 of 96.5 nM (WO2020081154A1, example 19) .
loading...
    loading...
Cat. No.: HY-P6010
Target:  

Integrin

Research Areas:  

Cancer

αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging .
loading...
    loading...